Anthony Purcell, DO
Family Medicine · Danielson, CTNPI 1548245491
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 788 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 48 manufacturers, the largest accounting for just 17.7% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 788 payments — averaging $18.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Novo Nordisk$2K
- Boehringer Ingelheim$1K
- GSK$1K
- AstraZeneca$1K
- Lilly USA, LLC$665
- plus $6K from 42 others
What the payments were for
- Food & beverage$14,19398%
- Education$2502%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,444 in reported general payments places this provider in the 95th percentile of 588 family medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 120 | $124,997 |
| OzempicSemaglutide | 68 | $103,945 |
| XareltoRivaroxaban | 44 | $59,611 |
| JardianceEmpagliflozin | 50 | $58,710 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 39 | $45,132 |
| JanuviaSitagliptin Phosphate | 31 | $40,910 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 28 | $40,767 |
| RexultiBrexpiprazole | 24 | $37,424 |
| FarxigaDapagliflozin Propanediol | 29 | $37,302 |
| TrulicityDulaglutide | 12 | $29,840 |
| Breo ElliptaFluticasone/Vilanterol | 37 | $27,288 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 17 | $23,405 |
| MyrbetriqMirabegron | 39 | $23,031 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 17 | $22,690 |
| RybelsusSemaglutide | 13 | $21,493 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,841 | $125,43881 claims |
| PfizerEliquis | $642 | $124,997120 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat, Combivent Respimat | $1,304 | $99,91881 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $1,060 | $95,11093 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Brilinta, Nexium | $1,043 | $92,874101 claims |
| Johnson & JohnsonXarelto | $117 | $59,61144 claims |
| MerckJanuvia, Dulera | $231 | $47,78042 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $665 | $47,50228 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $389 | $37,42424 claims |
| Astellas Pharma US IncMyrbetriq | $317 | $23,03139 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $373 | $14,29611 claims |
| AbbVieLinzess | $2,562 | $12,10916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 588 family medicine providers in Connecticut.
Other family medicine in Danielson
- Eunice AsomaningDanielson$8K
- Alan RuizDanielson$5K
- Theodore BrunoDurham$201K
- Kenneth DardickStorrs$146K
- Raymond KurkerSouth Windsor$107K
- Thao DoranMarlborough$102K
- Raja FattalehPutnam$53K
- Nicholas TzikasNew Haven$46K
- Helar CamposNew London$29K
- Kristin GianniniVernon$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.